Krystal Biotech (KRYS) Debt Ratio (2016)

Krystal Biotech (KRYS) posted quarterly Debt Ratio of 0.32 for Q4 2016.

Krystal Biotech (KRYS) Debt Ratio (2016) Analysis & Trends

Krystal Biotech has reported Debt Ratio for 1 years, with the latest figure at 0.32 in Q4 2016.

Debt Ratio for Q4 2016 came in at 0.32, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was 0.32 (changed N/A YoY), and the FY2016 annual result was 0.32, changed N/A from the prior year.
Debt Ratio held at 0.32 in Q4 2016.
Over five years, Debt Ratio peaked at 0.32 in Q4 2016 and troughed at 0.32 in Q4 2016.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Krystal Biotech	9.83 Bn	8.99 Bn	112.79 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2016	0.32